Increasing Prevalence of IBS to Augment Growth of the Irritable Bowel Syndrome Treatment Market

 

Irritable bowel syndrome (IBS) is among the common disorders of the large intestine. Signs and symptoms include gas, bloating, abdominal pain, cramping, and constipation or diarrhea, or both. A diagnosis is usually made centered on symptoms. Simple changes in diet and lifestyle often provide relief from IBS. Others need medication and counselling. Medications approved for treating IBS include Alosetron (Lotronex), Eluxadoline (Viberzi), Rifaximin (Xifaxan), Lubiprostone (Amitiza), and Linaclotide (Linzess).

Competitive Analysis:

Major players operating in the Irritable Bowel Syndrome Treatment Market are Synergy Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., GlaxoSmithKline Plc. Novartis AG, Astellas Pharma Inc., Ardelyx, Inc., Sucampo Pharmaceuticals, Inc., Abbott Laboratories, and Valeant Pharmaceuticals International, Inc.

Major market players are adopting various strategies, such as for example research and development, to develop safe and effective IBS treatment. For example, in March 2021, Arena Pharmaceuticals announced topline results from Phase 2b CAPTIVATE clinical trial evaluating three doses of olorinab, a book, oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, in participants with abdominal pain because of Irritable Bowel Syndrome (IBS).

In November 2020 Urovant Sciences announced topline data from its Phase 2a study of vibegron for treating irritable bowel syndrome (IBS) pain that didn't meet its primary endpoint.

Market Dynamics:

Increasing incidence or prevalence of Irritable Bowel Syndrome Treatment worldwide, especially in North America, is likely to augment the growth of the irritable bowel syndrome treatment market. For example, according to the International Foundation for Gastrointestinal Disorders (IFFGD), around 45 million people in the United States have problems with IBS. About 2 in 3 IBS sufferers are female and about 1 in 3 are male.

Moreover, strategic initiatives undertaken by government and non-government organizations, to improve awareness among people about IBS, are likely to propel the growth of the irritable bowel syndrome treatment market. For example, in April 2020, IFFGD will join caregivers, nearest and dearest, and patients to improve public awareness about IBS.

Increasing penetration of advanced technologies, such as for example artificial intelligence (AI), in the healthcare industry is expected to provide lucrative growth opportunities for layers in the market. For example, a written report published in the Journal of Medical Internet Research, in March 2021, found preliminary evidence that Heali, an application that uses AI to make personalized nutrition simple, may provide therapeutic benefits to users with IBS. The app shown to enhance standard of living by 2.6x in patients with IBS in randomized controlled trial.